Equities
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.

  • Revenue in HKD (TTM)48.02bn
  • Net income in HKD18.66bn
  • Incorporated2000
  • Employees37.83k
  • Location
    WuXi AppTec Co Ltd228 Fute Zhong RoadWaigaoqiao Free Trade ZoneSHANGHAI 200131ChinaCHN
  • Phone+86 2 150461000
  • Fax+86 2 150463093
  • Websitehttps://www.wuxiapptec.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.